Lincoln Pharmaceuticals logo

Lincoln Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: LINCOLNBSE: 531633Pharmaceuticals & BiotechnologySmall Cap

Lincoln Pharmaceuticals Limited · Face value ₹10 · Listed Apr 1996 on BSE, Dec 2015 on NSE
Last close ₹558.10up ₹8.05 (1.46%)BSE ₹557.55

Share price at the NSE close on 28 Oct 2026. Previous close ₹550.05.

28 Oct: open ₹541.00, high ₹560.00, low ₹532.00

52-week range of traded prices to 28 Oct 2026
₹440.00Low, 28 Jan 2026₹770.00High, 27 May 2026
Market cap
₹1,118 Cr1,389th largest listed
P/E
11.59
P/B
1.48
Dividend yield
0.32%
ROE
13.5%
ROCE
11.3%
Debt to equity
0.01
Volume, NSE
47,20541.0% delivered

Lincoln Pharmaceuticals' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Lincoln Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
36127Mar 1736235Mar 1836649Mar 1938651Mar 2042462Mar 21472692.0Mar 22510732.0Mar 23581931.1Mar 24623820Mar 25671884.4Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
20.6%7.5%12.9%14.5%18.3%17.0%20.6%20.2%17.5%17.2%16.3%14.6%7.5%9.6%13.3%13.3%14.7%14.7%14.3%16.1%13.2%13.1%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹362 Cr, differs from its quarters added, ₹372 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue671
  2. Materials and goods−311
  3. Employee costs−125
  4. Other expenses−137
  5. Operating profit98
  6. Depreciation−14
  7. Other income+33
  8. One-off items0.0
  9. Finance costs−1.0
  10. Profit before tax116
  11. Tax−28
  12. Net profit88

What the company owns

  • Plant, investments and other assets₹408 Cr
  • Current investments₹209 Cr
  • Receivables₹161 Cr
  • Inventory₹80 Cr
  • Cash and bank₹33 Cr

What pays for it: net worth and liabilities

  • Net worth₹758 Cr
  • Owed to suppliers₹85 Cr
  • Other liabilities₹43 Cr
  • Borrowings₹4 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Lincoln Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Filed 28 MayJun 2026Twelve monthsFiled 13 Aug
Revenue from operations361362366386424472510581623671694
314309299321337377421481522573593
Materials and goods bought217193175183198219241278291311327
Employee costs38–5259617093103112125127
Other expenses59–727979888799118137139
Operating profit before depreciation4652676687958910010198101
Operating margin12.9%14.5%18.3%17.0%20.6%20.2%17.5%17.2%16.3%14.6%14.6%
Materials, % of revenue60.2%–47.9%47.3%46.6%46.3%47.3%47.9%46.7%46.4%47.1%
Employee costs, % of revenue10.4%–14.2%15.2%14.3%14.9%18.3%17.7%18.0%18.7%18.3%
Other expenses, % of revenue16.5%–19.6%20.5%18.5%18.6%17.0%17.1%18.9%20.4%20.1%
Depreciation and amortisation667788911131415
Operating profit after depreciation4146605880878089898386
Other income356116102234223342
Finance costs75422121211
One-off items00000000000
Profit before tax374662678496100122109116128
1012131621272829272831
Net profit2735495162697393828896
Other comprehensive income–––––000022
Total comprehensive income–––––697393829099
Net margin7.5%9.6%13.3%13.3%14.7%14.7%14.3%16.1%13.2%13.1%13.9%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Filed 28 May
433502593672758
Share capital2020202020
Reserves413482573652738
Borrowings22104
907292106111
1113151922
Total assets534587700797890
182220254297307
353367447500583
Net debt−114−124−152−196−237
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Filed 28 May
76396393106
1006989119131
2−31−16910
Receivables−3−20−26−56
Inventories−263−7−2−1
Payables15−2122130
Other working capital177−435
Tax paid−24−30−26−26−25
Capital spending4614391925
Free cash flow3125247481
−78−37−57−79−98
−3−5−5−60
Dividends paid33344
Shares bought back00000
Shares issued00000
Net change in cash−5−2188
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021.

Per share

Consolidated, ₹ per share, years to March.Lincoln Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Filed 28 May
Earnings per share₹15.14₹17.32₹24.33₹25.72₹31.11₹34.63₹36.40₹46.58₹41.11₹43.88
Diluted earnings per share₹15.14₹17.32₹24.33₹25.72₹31.11₹34.63₹36.40₹46.58₹41.11₹43.88
Dividend per share₹1.20₹1.50₹1.50₹1.50₹1.50₹1.50₹1.50₹1.80₹1.80₹1.80
Book value per share–––––₹216.12₹250.86₹295.98₹335.34₹378.25
Dividend payout8.9%8.7%6.2%5.8%4.8%4.3%4.1%3.9%4.4%4.1%
Shareholder yield–––––0.5%0.4%0.3%0.3%0.3%
Market cap at the year end (₹ crore)4724264232594506216801,1741,1051,132

Ratios

Consolidated, years to March.Lincoln Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Filed 28 May
Revenue growth−11.5%–1.3%5.5%9.8%11.3%8.1%13.8%7.4%7.7%
Operating profit growth−2.9%–28.4%−2.4%33.0%9.5%−6.6%12.0%1.6%−3.8%
Net profit growth14.3%28.0%40.5%5.8%21.0%11.4%5.1%28.0%−11.7%6.7%
Earnings per share growth–14.4%40.5%5.7%21.0%11.3%5.1%28.0%−11.7%6.7%
–––––16.0%15.6%17.0%13.0%12.3%
––––––−0.4 pts1.4 pts−4.0 pts−0.7 pts
From the net margin––––––−0.4 pts1.9 pts−3.0 pts−0.1 pts
From asset turnover––––––0.5 pts−0.2 pts−1.1 pts−0.6 pts
From borrowing––––––−0.5 pts−0.3 pts0.1 pts0.0 pts
Return on capital employed–––––20.1%15.9%15.0%13.2%10.9%
Cash conversion–––––109.8%53.9%67.8%113.0%121.0%
Interest cover5.98.515.128.851.060.239.460.947.182.1
Debt to equity–––––0.000.000.000.000.01
Receivable days–––––90981029788
Inventory days–––––1211061019994
Payable days–––––1207795106100
Cash conversion cycle, days–––––911261089082
Working capital days–––––115123127116128
Asset turnover–––––0.880.910.900.830.80
Assets per rupee of net worth–––––1.231.201.181.181.18
Sales per rupee of plant–––––3.593.403.243.433.53
Capital spending to depreciation–––––5.631.563.721.481.75
Plant being built, % of plant in use–––––12.2%4.5%1.9%2.5%2.8%
Revenue growth and operating profit growth are left blank for the year to Mar 2018: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
10.4%
Cash from operations against operating profit
108.9%
Measure10 years5 years3 years
Revenue growth, yearly rate–9.6%9.6%
Profit growth, yearly rate14.0%7.1%6.4%
Return on equity, average–14.8%14.1%
Return on capital employed, average–15.0%13.0%
Operating margin, average16.9%17.2%16.0%
Net margin, average13.0%14.3%14.1%
Asset turnover, average–0.860.84
Cash conversion cycle, days, average–9993
Interest cover, average39.958.063.4
Debt to equity, average–0.000.00

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations378263106
Cash from investing−349−235−98
Cash from financing−18−110
Capital spending1448425
Dividends paid16104
Shares bought back000
Shares issued for cash000
Borrowings raised110880
Borrowings repaid115954

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––––556
Altman Z-scorePublished threshold 1.81–––––6.838.009.728.278.10
Beneish M-scorePublished threshold −1.78––––––−1.86−2.17−2.41−2.65
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––––12.5313.589.129.47
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––0.760.791.00
Receivables growth less revenue growthOur threshold 0 percentage points––––––9.504.89−4.49−10.64
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––––––−14.17−5.11−2.71−5.00
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––––––−0.940.801.09−0.60
Assets under construction, years of additionsOur threshold 2 years of additions––––––0.240.090.290.23
Effective tax ratePublished threshold 17.16 per cent26.4725.0821.6523.4525.6527.7127.4523.6724.5823.98
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––3.01−2.022.280.492.24
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
28 Sep 2026ICRA LimitedInterchangeable limits-Others[ICRA]AReview, Re-affirmStable16
28 Sep 2026ICRA LimitedFund-based-Cash credit[ICRA]AReview, Re-affirmStable66
28 Sep 2026ICRA LimitedNon-fund based-Others[ICRA]A1Review, Re-affirm11
9 Jan 2026CRISIL Ratings LimitedBank FacilitiesCrisil A1Review, Re-affirm3
9 Jan 2026CRISIL Ratings LimitedBank FacilitiesCrisil AReview, Re-affirmStable16
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.